- Sperm Samples May Help Predict Autism Risk in Offspring
- AHA News: Baby Born With Heart Defect Faces More Challenges After Stroke
- U.S. COVID Vaccine Rollout Nears 1 Million Doses Per Day
- Health Highlights: Jan. 14, 2021
- More Breast Cancer Survivors Opting to ‘Go Flat’ After Mastectomy
- Even 1 Drink a Day May Raise Your Odds for A-Fib
- Smoking Raises Risk for Deadly ‘Bleeding Strokes’
- Stopping Common Heart Meds Could Be Risky for Kidney Patients
- First Computer Model of Entire COVID Virus Will Aid Research
- Climate Change Is Spurring Malnutrition in Kids Worldwide
Shark Cartilage Not Beneficial in Advanced Lung Cancer
WEDNESDAY, May 26A drug derived from shark cartilage failed to improve survival in patients with advanced lung cancer, researchers report.
The disappointing results, which came in the final stage of testing, showed that the drug didn’t help extend the life spans of patients with inoperable stage III non-small cell lung cancer.
Scientists have been testing drugs derived from shark cartilage because it appears to prevent blood vessels from growing around tumors. The hope is that the drugs will prevent cancer cells from being fed by blood, which allows them to grow.
Researchers led by Dr. Charles Lu, of the University of Texas M.D. Anderson Cancer Center, tested the specific drug in question, known as AE-941, on patients in the United States and Canada.
In the study, published online May 26 in the Journal of the National Cancer Institute, a total of 379 patients with inoperable non-small cell lung cancer were treated with chemoradiotherapy and either AE-941 or an inactive placebo.
There was no significant difference in outcome between the two groups in terms of overall survival, or in length of time before the disease progressed, the researchers found.
The study authors noted that the study’s impetus was “the widespread use of poorly regulated complementary and alternative medicine products, such as shark cartilage-derived agents, among patients with advanced cancer, a population likely to be vulnerable to unsubstantiated marketing claims.”
More information
For more on lung cancer, try the U.S. National Library of Medicine.
Source: HealthDay
